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UbiquitinationTranscription factor FOXP3 (forkhead box P3) is found initially as a key regulator in regulatory T cells. Recently its
expression has been demonstrated in some non-lymphoid normal and cancerous cells. Now FOXP3 has been
proven to regulate cancer-related genes, especially suppressor genes in breast cancer. But the mechanisms by
which FOXP3 regulates suppressor genes are not fully determined. In this study, we found the inverse correlation
between FOXP3 and Ezh2, an enzyme for histone H3K27 trimethylation (H3K27me3) and a central epigenetic
regulator in cancer. The overexpression of FOXP3 weakened Ezh2's enhancement on the mammosphere forma-
tion, cell proliferation, directional migration, and colony forming ability of T47D cells. We demonstrated that
FOXP3 could downregulate Ezh2 protein level and this depended on not only the FOXP3 expression amount,
but also the nuclear localization of FOXP3. More importantly, we demonstrated FOXP3 accelerated Ezh2 protein
degradation through the polyubiquitination–proteasome pathway by enhancing the transcription of E3 ligase
Praja1 directly. These results provided a newmechanism for FOXP3 in histonemodiﬁcations as an Ezh2 suppres-
sor and supported new evidence for FOXP3 as a tumor suppressor in breast cancer.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
FOXP3 (forkhead box P3) is a member of the forkhead/winged-helix
family of transcriptional regulators. It is associatedwith autoimmune dis-
eases as a vital transcription factor in CD4+CD25+ regulatory T cells [1].
Recently FOXP3 expression is demonstrated not restricted to the lym-
phocyte lineage and it could be expressed by somenon-lymphoidnormal
and cancerous cells [2]. FOXP3 has been identiﬁed as a crucial tumor sup-
pressor in breast cancer, with high expression level in normal breast ep-
ithelial cells and downregulated in the corresponding cancer cells [3].
Besides its roles in autoimmune disorders and tumorigenesis, increasing
studies demonstrated that there was an increased frequency of FOXP3+27me3, trimethylationof histone
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showed that FOXP3 could regulate the expression of both oncogenes
and tumor suppressor genes, including HER2/neu [3], SKP2 (S-phase
kinase-associated protein 2) [6], c-Myc [7], p21 (CDKN1A, CIP1, WAF1)
[8], and SATB1 (special AT-rich sequence binding protein 1) [9].
The chromatin structure is essential not only for the genomic com-
pact packaging but also for transcription regulation. Epigenetic his-
tone modiﬁcations are involved in tumorigenesis and progression.
Transcriptional activation and repression mediated by FOXP3 were
demonstrated to be associated with speciﬁc histone modiﬁcations at
its binding sites [10,11]. For example, FOXP3 speciﬁcally inhibited
binding of histone deacetylase 2 (HDAC2) and HDAC4 to p21 intron
1 and increased local histone H3 acetylation [8]. Polycomb group pro-
teins are vital chromatin regulators and are organized into at least
two main sets of protein complexes: PRC1 and PRC2. As a crucial
member of the PRC2, Ezh2 (enhancer of zeste homolog 2) is a central
epigenetic regulator of cell survival, proliferation, and stem cell
self-renewal [12–14]. It catalyzes trimethylation of histone H3 lysine
27 (H3K27me3) as a histone–lysine N-methyltransferase. In addition,
Ezh2 was reported to recruit other polycomb complexes, DNA
methyltransferases, and histone deacetylases, resulting in additional
transcriptional repressive marks and chromatin condensation at key
developmental loci [15].
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ﬁed in regulatory T cells and cancers, little is known about FOXP3's spe-
ciﬁcmechanism on chromatin remodeling. Here, we observed that there
was an inverse correlation in various conditions between FOXP3 and
Ezh2, a central epigenetic regulator in cancer. We demonstrated that
FOXP3 couldweaken Ezh2's enhancement on themammosphere forma-
tion, cell proliferation, directionalmigration, and colony forming abilities
of T47D cells. We demonstrated that FOXP3 could downregulate Ezh2
protein level and this depended on not only the FOXP3 expression
amount, but also the nuclear localization of FOXP3. More importantly,
we demonstrated that FOXP3 promoted Ezh2 protein degradation
through the polyubiquitination–proteasome pathway by enhancing
the transcription of E3 ligase Praja1 directly. These results provided a
newmechanism for FOXP3 in histonemodiﬁcations as an Ezh2 suppres-
sor and supported new evidence for FOXP3 as a tumor suppressor in
breast cancer.
2. Material and methods
2.1. DNA plasmids, shRNAs, and microRNAs
FOXP3 was ampliﬁed from cDNA of human peripheral blood mono-
nuclear cells (under a protocol approved by the Institutional Review
Board) by RT-PCR with HA tag introduced into 5′ end. The PCR products
were then cloned into retrovirus/lentivirus vectors of pMigRI-GFP,
pMSCV-puro and pLenti-CMV/TO-puro respectively, which were con-
ﬁrmed by sequencing. FOXP3 K227R construct was a gift from Prof.
Pan Zheng (University of Michigan School of Medicine and Cancer
Center) and was subcloned into pMSCV-puro. Praja1 was cloned into
pBabe-hygro from C57BL/6 mouse with HA tag introduced into 5′ end.
pBabe-myc-Ezh2-bleo, pLenti-CMV-TetR-Blast, pLenti-CMV-neo and
lentiviral shRNA for Ezh2 were gifts from Dr. Filippos Kottakis and
Prof. Philip N. Tsichlis (Tufts University School of Medicine). Lentiviral
shRNAs for FOXP3 and Praja1 were from Sigma. Ubiquitin construct
was a gift from Dr. Christos Polytarchou (Harvard Medical School) and
was subcloned into pLenti-CMV-neo with Flag-tag introduced into 5′
end. WWP1 construct was a gift from Prof. Laurie H. Glimcher (Harvard
Medical School). ChIP constructwas a gift fromProf. CamPatterson (Uni-
versity of North Carolina). miR-101 (AM17100-PM11414), miR-control
(AM17110), antagomiR-101 (AM17000-AM11414) and antagomiR-
control (AM17010) were purchased from Ambion (Austin, USA).
2.2. Cell lines
Mouse lung ﬁbroblasts were established by fresh tissue samples
from neonatal BALB/c mouse and were cultured in Dulbecco's Modi-
ﬁed Eagle Medium (DMEM) supplemented with 2 mM L-Glutamine,
10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml strepto-
mycin (Cellgro, Mediatech Inc.). HEK293, MDA-MB-231, MCF-7 and
T47D cells (ATCC, Manassas, VA, USA) were cultured in the same me-
dium as ﬁbroblasts. MCF-10A cells (ATCC) were cultured as described
[16]. Cell lines stably expressing target gene(s) were established by
standard operating procedures (Supplementary material).
2.3. Western blot
Protein samples from total cell lysates were subjected to 10% sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis analysis and
electrotransferredontopolyvinylideneﬂuoridemembrane. After blocking
for 1 h with 5% BSA or fat-free milk, membranes were probed with the
indicated primary antibodies overnight (anti-HA, anti-Myc, anti-Ezh2
and anti-H3K27me3 from Cell Signaling Technology; anti-FOXP3 from
Abcam; anti-Flag, anti-Praja1 and anti-tubulin from Sigma), followed by
horseradish peroxidase-conjugated secondary antibodies for 1 h at
room temperature. Membranes were then washed and visualized with
chemiluminescence detection system (GE Healthcare).2.4. Mammosphere formation
Equal numbers of single-cell suspensions digested with trypsin
were seeded and cultured in non-adherent 6-well ultra-low attach-
ment plates (Corning, MA, USA) in serum-free medium for 21 days
at 37 °C in 5% CO2. Primary mammospheres were collected by gentle
centrifugation. Equal numbers of single-cell suspensions digested
with trypsin from primary mammospheres were seeded again in
nonadherent 6-well ultra-low attachment plates. After 15 days at
37 °C in 5% CO2, secondary mammospheres were collected by gentle
centrifugation and counted under a microscope.2.5. Cell growth
Cells from primary mammospheres were seeded and cell growth
was evaluated by directly counting cell numbers using a microscope
counting chamber (hemocytometer). After complete trypsinization,
the ﬂoating cells were mixed with 0.4% trypan blue dye before
being loaded onto the counting chamber. For each sample, the cell
number was counted three times.2.6. Wound healing assay (directional cell migration)
When cells from primary mammospheres were grown to 90% con-
ﬂuence, artiﬁcial wounds were generated on the cell monolayer using
a 200-μl disposable pipette tip. Migrated cells and wound healing
were visualized at 0 and 72 h.2.7. Colony formation assay
Equal numbers of cells from primary mammospheres were seed-
ed into 6-well tissue culture plates in triplicate, and incubated for
15 days at 37 °C in 5% CO2. Colonies were washed and ﬁxed in 4%
formaldehyde solution in PBS, and then stained with Coomassie
blue.2.8. Alkaline comet assay
Alkaline comet assay was performed as described [17]. At least 50
cells per samples were analyzed by using a CometScore software
(http://autocomet.com/products_cometscore.php).2.9. Real-time quantitative PCR
Total RNAwas isolated from cells with trizol (Invitrogen) and cDNA
was synthesized using the Super-Script kit from Invitrogen. Real-time
quantitative PCR in triplicate using SYBR Green master mix (QIAGEN,
Shanghai, China) was performed on DNA Engine Opticon® 2 System.
The primers used were listed in the Supplementary material. mRNA
levels were measured by the relative ﬂuorescent intensity to the inter-
nal control, GAPDH.2.10. MicroRNA real-time quantitative PCR analysis
miR-101 levels in cultured cells were measured by real-time
RT-PCR and normalized to U6 small nuclear RNA (snRNA, internal
control). Total RNA was isolated using trizol and reverse transcription
was performed using a ﬁrst-strand cDNA synthesis kit (Exiqon, MA,
USA) with speciﬁc primer sets for miR-101 (Exiqon, 202133) and
U6 snRNA (Exiqon, 201510). Real-time PCR was performed in tripli-
cate using the SYBR Green master mix (Exiqon). The rest was
performed as above in “2.9 real-time quantitative PCR”.
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Cells grown on sterile glass were washed with PBS extensively and
ﬁxedwith 4% paraformaldehyde solution for 20 min, followed by perme-
abilizationwith 0.2% Triton X-100/3% horse serum in PBS for 30 min. Fol-
lowing washes by PBS, anti-human FOXP3-FITC (eBioscience, CA, USA)
was added to the cells for 60 min at room temperature. Cells were then
counterstained with 4′, 6′-diamidino-2-phenylindole (DAPI, Sigma) for
5 min. Tissue sampleswere taken under a protocol approved by the Insti-
tutional Review Board of Southwest Hospital. Written, informed consent
was obtained from each subject. 4 μm sections of formalin-ﬁxed parafﬁn
embedded breast cancer tissues were mounted on slides coated with
poly-L-lysine. Sections were dewaxed, permeabilized and blocked (PBS
plus 5% goat serum) routinely. Primary antibodies (mouse anti-human
FOXP3antibody, Biolegend; rabbit anti-humanEzh2 antibody, Cell Signal-
ing) were diluted in blocking buffer and applied to the sections overnight
at 4 °C. Afterwashing, diluted secondary antibodies (Cy5-conjugated goat
anti-mouse mAb and Alexa F488-conjugated goat anti-rabbit mAb) were
applied onto the sections for 60 min at room temperature. Nuclei were
counterstained with DAPI. Images were obtained on a Nikon ECLIPSE
80i ﬂuorescence microscope with a digital camera and captured by a
SPOT Advanced™ software.
2.12. Immunoprecipitation (IP)
After washing, cells were collected and lysed in the presence of
cold 1× IP buffer (1% Triton X-100, 150 mM NaCl, 25 mM Tris
pH 7.6, 0.5 mM EDTA, 0.5 mM EGTA pH 8.0, 0.2 mM PMSF, 0.5%
NP-40, 0.5 mM DTT, 2.5% glycerol, and 5 mM beta-glycerol phos-
phate). Protein lysates were precleared by protein G-sepharose
beads (Pierce) with constant rotation for 60 min at 4 °C. Primary an-
tibodies (anti-Myc from Cell Signaling Technology,anti-Flag from
Sigma) were added respectively into the cleared lysates and incubat-
ed with constant rotation for 4 h at 4 °C. Protein G-sepharose beads
were then incubated to capture the primary antibody for another
90 min at 4 °C. Captured immunoprecipitates were washed four
times with 1× IP buffer and two times with low-salt buffer (20 mM
Tris pH 7.4, 25 mM NaCl, and 1 mM DTT). Immunoprecipitates were
then denatured and separated from the sepharose beads by adding
SDS loading buffer and boiling for 10 min.
2.13. Chromatin immunoprecipitation (ChIP)
The Pierce Agarose ChIP Kit was purchased from Theromo Scientiﬁc.
MCF-7 cells were cultured as described above, and ChIP assays were
performed following ultrasonic shearing eight times for 30 s in a
water bath sonicator that result in relatively uniform DNA fragment
size of ∼300 bp. The immunoprecipitation was performed using goat
anti-human FOXP3 antibody (Abcam, Cambridge, UK) at the concentra-
tion of 0.2 μg/μg chromatin. Puriﬁcation of genomic DNA (ChIP samples
and input) was performed by phenol/chloroform extraction, and the
speciﬁc fragments of Praja1 promoter sequences from IgG-treated
(negative control), immunoprecipitated (ChIP sample) and input (pos-
itive control) DNAswere respectively detected by PCR reaction of 2 μl of
each DNA sample. The primer pairs used for PCR to amplify Praja1 pro-
moter region containing FOXP3 binding elements were listed in the
Supplementary material.Fig. 1. FOXP3 showed an inverse correlation with Ezh2 protein. The relative protein levels of FO
Inset showed representative one). The relative quantity of target protein to Tubulin was identiﬁ
tively). (A) Mouse lung ﬁbroblast cells were cultured in DMEMwith supplements and were pa
was maintained in low serum (0.2%) DMEM for indicated time. The lower insets showed the c
morigenic MDA-MB-231, T47D andMCF-7 breast cancer cells were cultured in DMEMwith sup
were cultured in DMEM with supplements and doxorubicin (1.5 μg/ml) was added to cause D
measured by “Olive tail moment” parameter (http://autocomet.com/products_cometscore.ph
in breast cancer tissues with or without FOXP3 mutation (n = 3, taken at 400× magniﬁcation2.14. Statistical analysis
Statistical differences were determined using Student t-test. The re-
sults were considered signiﬁcantly different when p valuewas less than
0.05.
3. Results
3.1. FOXP3 showed an inverse correlation with Ezh2
In this section, we investigated the expression levels of FOXP3 and
Ezh2 in different cells and under several conditions. First, we found
that FOXP3 expression in mouse lung ﬁbroblast cells was increased
along with cell passages by Western blot, while Ezh2 and H3K27me3
expression levels were decreased (FOXP3: t = 13.8229, p b 0.0001;
Ezh2: t = 15.8674, p b 0.0001; and H3K27me3: t = 9.4951, p =
0.0001, passage 1 vs.10, Fig. 1A). Next, we starved MCF-10A cells, a
non-tumorigenic mammary gland cell line, by maintaining them in low
serum (0.2%) for indicated time. Long-term serum starvation increased
the expression of FOXP3 and decreased Ezh2 and H3K27me3 expression
levels (FOXP3: t = 12.6875, p b 0.0001; Ezh2: t = 7.8107, p = 0.0002;
and H3K27me3: t = 7.0234, p = 0.0004, day 1 vs.15, Fig. 1B). Both
FOXP3 and Ezh2 were reported to be involved in breast cancer [3,9]. So
we next compared FOXP3 and Ezh2 in non-tumorigenic MCF-10A and
breast cancer cells (MDA-MB-231, T47D and MCF-7). We found that
there was a higher level of FOXP3 in MCF-10A, compared with tumori-
genic MDA-MB-231, T47D and MCF-7 cells respectively (t = 46.9477,
p b 0.0001, t = 15.8603, p b 0.0001, and t = 34.2675, p b 0.0001,
Fig. 1C), which was consistent with published results [3]. The level of
Ezh2 showed inverse correlation with FOXP3. There were lower
levels of Ezh2 and H3K27me3 in MCF-10A, compared with those in
tumorigenic MDA-MB-231, T47D and MCF-7 cells respectively
(Ezh2: t′ = 12.7651, p b 0.01, t′ = 8.1828, p b 0.01, t′ = 6.8557,
p b 0.01; H3K27me3: t′ = 10.9227, p b 0.01, t′ = 4.0932, p b 0.01,
and t′ = 3.1849, p b 0.01, Fig. 1C). Finally, we tried to investigate
the expression levels of FOXP3 and Ezh2 under the condition of in-
creased DNA damage. As shown in Fig. 1D, DNA damage caused by
doxorubicin (1.5 μg/ml) in MCF-7 cells upregulated FOXP3 level, ac-
companied with decreased Ezh2 and H3K27me3 levels (FOXP3: t =
8.0538, p = 0.0002; Ezh2: t = 5.201, p = 0.002; and H3K27me3:
t = 5.707, p = 0.0013, zero vs. 4 h point, Fig. 1D). This result indi-
rectly supported previous studies indicating that Ezh2 was associat-
ed with repair responses of DNA damage [18].When Ezh2 and FOXP3
were co-stained by immunoﬂuorescence in breast cancer tissues
with or without FOXP3mutation, we found that breast cancer tissues
with FOXP3 mutation showed a higher level of Ezh2 expression, con-
sistent with the idea that FOXP3 repressed Ezh2 (Fig. 1E). Collective-
ly, results in this section demonstrated that FOXP3 showed an
inverse correlation with Ezh2 protein and suggested its role in chro-
matin remodeling.
3.2. FOXP3 reduced Ezh2's promotion of mammosphere formation, cell
proliferation, migration, and colony forming abilities
Ezh2 has oncogenic and self-renewal roles in human cancer,
particularly in prostate and breast cancer. In this section, we found that
T47D/Ezh2 cells (Supplementary material) showed more and larger
secondary mammospheres (t = 3.4128, p = 0.0143), reinforced cellXP3, Ezh2 and H3K27me3weremeasured byWestern blot (n = 4 in panels A, B, C and D.
ed as 1 at the ﬁrst point/object (p1, day 1,MCF-10A and 0 h at panels A, B, C and D respec-
ssaged every three to four days. (B) Non-tumorigenic MCF-10A mammary gland cell line
hange of cell appearance during serum starvation. (C) Non-tumorigenic MCF-10A and tu-
plements. 10A:MCF-10A, 231:MDA-MB-231, 47D: T47D, and F7: MCF-7. (D) MCF-7 cells
NA damage. The lower inset showed the DNA damage detected by alkaline comet assay,
p) (n = 4). (E) Ezh2 (green) and FOXP3 (red) were co-stained by immunoﬂuorescence
).
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p b 0.0001) and colony forming ability (t = 3.91, p = 0.0174) than
empty-vector cells (Fig. 2A1–A4). Stable expression of wild-type FOXP3
in T47D/Ezh2 (T47D/Ezh2/FOXP3, Supplementary material) remarkably
decreased Ezh2 protein level (Fig. 2B2). Compared with T47D/Ezh2/
MigRI cells, T47D/Ezh2/FOXP3 cells showed less and smaller secondary
mammospheres (t = 4.5276, p = 0.0040), attenuated cell proliferation
(t = 2.533, p = 0.0445, at day 3), migration (t = 3.2796, p = 0.0168),
and colony formation (t = 3.0069, p = 0.0397) (Fig. 2B1–B4). FOXP3
knockdown with shRNA in T47D/Ezh2/FOXP3 cells (T47D/Ezh2/FOXP3/
shRNA-FOXP3, Supplementary material) rescued Ezh2 expression
(Fig. 2C2). This Ezh2 rescue reinforced secondary mammospheres
(t = 5.7976, p = 0.0012), cell proliferation (t = 4.0692, p = 0.0066,
at day 3), migration (t = 8.3143, p = 0.0002), and colony formation
(t = 6.8296, p = 0.0024), compared with empty-vector cells
(Fig. 2C1–C4). Results in this section suggested that FOXP3 reduced
Ezh2's promotion of mammosphere formation, cell proliferation, migra-
tion, and colony forming abilities.3.3. FOXP3 showed attenuated inhibitory effects on secondary
mammosphere, cell proliferation, migration and colony formation in
cells with Ezh2 knockdown
In order to further conﬁrm Ezh2's important roles in FOXP3 as a
tumor suppressor, we built T47D cells with silent Ezh2 by shRNA
(T47D/shRNA-Ezh2, Supplementary material). Although stable expres-
sion of MigRI-HA-FOXP3 in T47D/shRNA-Ezh2 cells could decrease the
secondary mammosphere, cell proliferation, migration and colony
formation, the differences between FOXP3 and its empty vector were
not statistically signiﬁcant (for secondary mammosphere formation,
t = 0.8, p = 0.4542; for cell proliferation, t = 1.6, p = 0.1607; for mi-
gration, t = 1.3131, p = 0.2371; and for colony formation, t = 2.3717,
p = 0.0767, respectively, Fig. 3). These results showed that the inhibito-
ry effects of FOXP3were attenuated in T47D cellswithout Ezh2. Integrat-
ing the above results, we concluded that Ezh2 was likely a main
downstream of FOXP3. By downregulation of Ezh2, FOXP3 inhibited
the mammosphere formation, cell proliferation, migration, and colony
formation in T47D cells.3.4. Downregulation of Ezh2 by FOXP3depended onnot only the expression
level, but also the nuclear localization of FOXP3
In order to investigate whether the downregulation of Ezh2 was
FOXP3 dose-dependent, in this section we built doxycycline-responsive,
FOXP3 conditionally-expressed T47D cells by sequential infections and
selections of pLenti-CMV-TetR-Blast, pBabe-myc-Ezh2-Bleo and pLenti-
CMV/TO-HA-FOXP3-puro (Supplementary material). We found that in-
creased FOXP3 induced by doxycycline was accompanied by gradually
decreased Ezh2 (Fig. 3E). This result suggested that the downregulation
level of Ezh2 by FOXP3 depended on FOXP3 expression level.
As a transcription factor, FOXP3 constitutively translocates into the
nucleus where it binds to speciﬁc sequences of DNA to regulate the
transcription of its target genes.Missensemutation (K227R, from lysine
to arginine) was previously reported in breast cancer and prostate
intraepithelial neoplasia. Defect in nuclear localization caused by
K227R had been veriﬁed to be sufﬁcient to abrogate growth inhibition
by FOXP3 in tumor cells [3,7]. Here our results conﬁrmed that K227R
impaired the nuclear localization of FOXP3, with quite a few FOXP3
retention in cytoplasm (Fig. 3F). Although comparable total FOXP3
levels, this impaired nuclear localization by K227R remarkably attenu-
ated FOXP3's ability to decrease Ezh2, compared with wild-type (t =
6.0869, p = 0.0037, Fig. 3F). Results in this section demonstrated that
downregulation of Ezh2 by FOXP3 depended on not only the expression
level, but also the nuclear localization of FOXP3.3.5. miR-101-Ezh2wasnot the responsible pathway for the downregulation
of Ezh2 by FOXP3
MicroRNA-101 (miR-101) is known to target Ezh2 mRNA [19].
Deletions of miR-101 have been reported in cancers and can lead to
overexpression of Ezh2 in several types of cancers [19,20]. In this sec-
tion, we conﬁrmed miR-101's negative impact on Ezh2 mRNA
transcription. Transfection of miR-101 into T47D/Ezh2/FOXP3 cells sig-
niﬁcantly decreased Ezh2mRNA level, comparedwith the scramble con-
trol (t = 5.4576, p = 0.0055, Fig. 4E). Transfection of antagomiR-101
remarkably rescued the decrease of Ezh2 mRNA (t = 5.9293, p =
0.0041, compared with control antagomiR, Fig. 4F). Next, we checked
the mRNA levels of Ezh2 and miR-101 in T47D/Ezh2/FOXP3 and T47D/
Ezh2/MigRI cells. We found that there were higher miR-101 and lower
Ezh2 mRNA levels in T47D/Ezh2/FOXP3 cells than in T47D/Ezh2/MigRI
cells (for miR-101, t = 5.1824, p = 0.0066; and for Ezh2, t = 7.3383,
p = 0.0018, Fig. 4C and A). These results suggested that miR-101
might be amediator between Ezh2 and FOXP3. However, this was elim-
inated by following themeasurement of Ezh2 andmiR-101mRNA levels
in T47D/Ezh2/FOXP3/sh-FOXP3 and T47D/Ezh2/FOXP3/pLKO.1 cells.
FOXP3 silence by shRNA failed to decrease miR-101 and increase Ezh2
mRNA levels (for miR-101, t = 0.7807, p = 0.4786; and for Ezh2,
t = 1.5712, p = 0.1912, Fig. 4D and B). This non-signiﬁcant change
suggested that the down-regulation of Ezh2 mRNA by miR-101 was
not merely caused by FOXP3. miR-101-Ezh2 was not the responsible
pathway for the downregulation of Ezh2 by FOXP3.
3.6. FOXP3 promoted the degradation of Ezh2 protein through K48-
linkage polyubiquitination
In Fig. 1A, we found that Ezh2 protein levels were signiﬁcantly
decreased when mouse lung ﬁbroblast cells were passaged from
passage 1 to 5 (t = 6.4841, p = 0.0006). What was not consistent
with this Ezh2 protein's decrease was that the level of Ezh2 mRNA
was not varied remarkably (t = 0.0456, p = 0.9651, Fig. 5A). In
addition, we noticed that the variations of Ezh2 mRNA in Fig. 4
(A and B) were not as signiﬁcant as those of Ezh2 protein in Fig. 2
(B2 and C2). These discrepancies promoted us to further investigate
Ezh2 post-translational modiﬁcation which could mediate its
degradation.
The ubiquitin proteasome pathway controls degradation of the
majority of regulatory eukaryotic proteins including those that
play key roles in tumorigenesis [21]. In this section, we found that
FOXP3 signiﬁcantly decreased Ezh2 protein half life by cyclohexi-
mide chase assay (Fig. 5B). MG132, a proteasome inhibitor, could
protect Ezh2 from degradation (Fig. 5C). These suggested a role of
proteasome degradation by ubiquitination in Ezh2 stability. Next,
we demonstrated this suggestion by comparing the ubiquitination
levels in T47D/Ezh2/MigRI and T47D/Ezh2/FOXP3 cells. We found
that FOXP3 remarkably attenuated Ezh2 protein level by enhancing
its polyubiquitination (Fig. 5D). Ubiquitination via ubiquitin lysines
is always involved in important cellular events, among which
ubiquitination via lysine 48 (K48) is often coupled to protein degra-
dation by the 26S proteasome pathway. In this section, we found
that ubiquitin mutant of K48R (lysine at 48 was mutated into
arginine) almost abolished the ubiquitination of Ezh2, accompanied
with rescued Ezh2 protein level (Fig. 5E). These results conﬁrmed
the ubiquitination of Ezh2 in mammalian cells and demonstrated
that FOXP3 promoted the degradation of Ezh2 protein by
proteasome pathway through K48-linkage polyubiquitination.
3.7. FOXP3 directly interacted with the promoter of Praja1, an E3 ubiquitin
ligase, and promoted its mRNA transcription
Ubiquitination of proteins involves the concerted action of E1
ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes
2195Z. Shen et al. / Biochimica et Biophysica Acta 1833 (2013) 2190–2200and E3 ubiquitin–protein ligases. The substrate speciﬁcity was
determined by E3 ubiquitin ligases. In this section, we tried to identify
the E3 ubiquitin ligase for Ezh2 ubiquitination. We screened the
following E3 ligases by their ability of Ezh2 degradation whenFig. 2. FOXP3 reduced Ezh2's promotion of mammosphere formation, cell growth, migration,
formation (n = 4, see Material and methods). Insets showed the representative ﬁelds. A2,
Myc-Ezh2 after infection of pBabe-Myc-Ezh2-Bleo retrovirus in T47D cells. Inset in B2 sho
Ezh2 cells. Inset in C2 showed the restoration of Myc-Ezh2 after infection of shRNA-FOXP3
blots were representative experiments of four. A3, B3 and C3 showed the results of wound h
formation (n = 3, see Material and methods). Colonies were calculated with the softwareco-transfected into 293 cells with Ezh2: Itch and WWP1 (HECT type
E3), TRAF6, Praja1 and ChIP (RING/U-box type E3). We happened to
ﬁnd that Praja1 could decrease Ezh2 protein level (Fig. 6H, other
data not shown).and colony formation of T47D cells. A1, B1 and C1 showed the results of mammosphere
B2 and C2 showed the cell growth curve (n = 4). Inset in A2 showed the increase of
wed the decrease of Myc-Ezh2 after infection of MigRI-HA-FOXP3 retrovirus in T47D/
(shRNA #1, Fig. 1s in the Supplementary material) in T47D/Ezh2/FOXP3 cells. Western
ealing (n = 4, see Material and methods). A4, B4 and C4 showed the results of colony
of Grid Cell Counter (Heracle BioSoft S.R.L.).
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mRNA levels in non-tumorigenic MCF-10A and tumorigenic T47D,
MDA-MB-231 and MCF-7 cells. We found that Praja1 mRNA level was
higher in MCF-10A than in breast cancer cell lines, with the lowest
level in highly invasive MDA-MB-231 cells (Fig. 6A). This transcriptionFig. 3. FOXP3 showed attenuated inhibitory effects in cells with Ezh2 knockdown (A, B, C and D)
localization of FOXP3 (E and F). The results of mammosphere formation (A), cell growth (B), dir
shRNA-Ezh2/FOXP3 T47D cells (n = 4, seeMaterial andmethods and the Supplementarymateri
B (one representative of four) showed increased HA-FOXP3 after infection of MigRI-H
conditionally-expressed T47D cells were built as described in the Supplementary material. FOXP
FOXP3 wild-type or K227R mutant were built (Supplementary material). The subcellular localiz
ﬁcation). The Ezh2 protein levels between FOXP3 wild-type and K227R mutant cells were comppattern of Praja1 in non-tumorigenic and tumorigenic cells was coinci-
dent with FOXP3 and opposite to Ezh2 in Fig. 1C. Similar results were
obtained when compared to MCF-10A cells in full and low-serum me-
diums. Starvation by low-serum medium signiﬁcantly increased Praja1
mRNA levels (Fig. 6B). This increasing tendency was parallel to that of. Downregulation of Ezh2 by FOXP3 depended on both the expression level and the nuclear
ectional migration (C) and colony formation (D) were compared in shRNA-Ezh2/MigRI and
al, shRNA-Ezh2 used in this study has been validated inMol Cell. 2011;43:285–298). Inset in
A-FOXP3 retrovirus in shRNA-Ezh2 T47D cells. (E) Doxycycline-responsive, FOXP3
3 and Ezh2 levels weremeasured byWestern blot (n = 3). (F) T47D cells stably expressing
ation of FOXP3 was shown by immunoﬂuorescence staining (n = 3, taken at 400× magni-
ared by Western blot. Inset showed representative one.
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Praja1 transcription was increased in a dose-dependent manner in
doxycycline-responsive, FOXP3 conditionally-expressed T47D cells
(doxycycline 30 ng/ml vs. medium, t = 4.1255, p = 0.0145; and
300 ng/ml vs. 30 ng/ml, t = 3.8986, p = 0.0176). These observations
promoted us to investigatewhether FOXP3 could regulate the transcrip-
tion of Praja1mRNA. This was further suggested by T47D cells stably ex-
pressing FOXP3 wild-type or K227Rmutant. Nuclear localization failure
by K227R apparently prevented the promotion of Praja1 mRNA tran-
scription by FOXP3 (t = 13.1291, p = 0.0002, Fig. 6D).
Based on the above observations, we demonstrated that FOXP3
overexpression increased and FOXP3 knockdown decreased Praja1
mRNA transcription respectively (t = 8.0299, p = 0.0013, Fig. 6E; and
t = 7.5429, p = 0.0017, Fig. 6F). We next addressed whether Praja1
transcription was regulated through binding its promoter by FOXP3 di-
rectly. FOXP3 is a member of a superfamily of evolutionarily conserved
transcriptional regulators, and plays a crucial role in the development
and progression of cancer [22]. The core consensus element for FOXP3
binding contains the sequences 5′(G/A)TAAACA3′ and 5′(A/G)(T/C)
AAACA3′ [23–25]. Therefore, we analyzed the 2000 bp DNA sequence
of Praja1 upstream of its translation starting site (Gene ID: 64219). We
found three FOXP3 consensus sites within the promoter region between
−1030 and−618 bp (Fig. 6G), suggesting that FOXP3 may bind Praja1Fig. 4.miR-101-Ezh2 was not the responsible pathway for the downregulation of Ezh2
by FOXP3. mRNA levels of Ezh2 and miR-101 were analyzed in T47D/Ezh2/FOXP3 and
T47D/Ezh2/MigRI cells (A and C), and T47D/Ezh2/FOXP3/sh-FOXP3 and T47D/Ezh2/
FOXP3/pLKO.1 cells (B and D, only shRNA #1 for FOXP3 was shown, Fig. 1s in the Sup-
plementary material) by real-time quantitative RT-PCR and microRNA real-time quan-
titative PCR respectively (n = 3). (E and F) T47D/Ezh2/FOXP3 cells were transfected
with 80 nM miR-101 or antagomiR-101 or their scramble controls. Ezh2 mRNA levels
were measured by the relative ﬂuorescent intensity to the internal control (GAPDH)
through real-time quantitative RT-PCR (n = 3).promoter directly. As shown in Fig. 6G, ChIP analysis demonstrated that
FOXP3 directly bound to Praja1 promoter, whereas FOXP3 could not
bind to the remote region of Praja1 (−2800 site upstream from Praja1
translation starting site), which does not contain FOXP3 consensus site.
Accordingly, FOXP3overexpression increased and FOXP3knockdownde-
creased Praja1 protein levels respectively (Fig. 4s in the Supplementary
material). In brief, results in this section demonstrated that FOXP3 direct-
ly interactedwith the promoter of Praja1, an E3 ubiquitin ligase, and pro-
moted its mRNA transcription.
3.8. Praja1 was one of the E3 ligases mediating Ezh2's polyubiquitination
and subsequent degradation
In this section, we tried to answer whether Praja1 bound to Ezh2
and mediated Ezh2's polyubiquitination and subsequent degrada-
tion. First, we demonstrated the interaction between Praja1 and
Ezh2 by immunoprecipitation (Fig. 6H). Next, we found that the
protein level of ectopically expressed Myc-Ezh2 was markedly
decreased when Praja1was co-expressed. This decrease was accom-
panied by the increase of Ezh2 polyubiquitination (Fig. 6H). Howev-
er, silence of Praja1 by shRNA failed to rescue Ezh2 protein and
decrease its polyubiquitination (Fig. 6I). This unexpected result sug-
gested that there must be other E3 ligase(s) responsible for Ezh2
polyubiquitination. These results further conﬁrmed that Ezh2 was
ubiquitinated in mammalian cells and demonstrated that Praja1
was involved in this ubiquitination process.
4. Discussion
It has been known that epigenetic regulation of tumor suppressor
genes is one of the most common molecular modiﬁcations in tumori-
genesis [26,27]. Post-translational modiﬁcations of the N-terminal
tails of core histones (e.g. methylation, acetylation, ubiquitylation and
phosphorylation) determine, at least in part, chromatin conﬁguration,
which can modulate accessibility of transcription factors [28]. Histone
methylation is dynamically regulated by both methyltransferases and
demethylases to turn the genome genes “off” or “on”. In general, meth-
ylation of histone H3 at lysine 4 (H3K4), H3K36, or H3K79 is associated
with active transcription, whereas methylation of H3K9, H3K27, or
H4K20 is associated with gene silencing [29].
Ezh2 is the core component of PRC2, themain chromatin regulator. It
catalyzes H3K27me3 formation and is essential in cell survival, prolifer-
ation, and cancer stem cell self-renewal [14]. Studies on human tumors
show that Ezh2 is frequently over-expressed in awide variety of cancer-
ous tissue types, including prostate cancer [30], and breast cancer [31].
In breast cancers, Ezh2 expression was elevated in invasive carcinoma
and metastases, and increased expression was strongly associated
with aggressive behavior and a poor clinical outcome [31].
Although the mechanistic contributions of Ezh2 to cancer pro-
gression are not yet determined, enhanced activity of Ezh2 leading
to epigenetic silencing of critical genes (e.g. tumor suppressor
genes) has been suggested to play an important role in tumor tumor-
igenesis [32]. Disruption of the PRC2 complex caused by siRNA to
Ezh2 increased tumor suppressors of cyclin-dependent kinase inhib-
itor family members of p16 (CDKN2A, NK4a), p21, and p27 (CDKN1B,
KIP1) [33].
FOXP3 was initially thought to be associated with autoimmune dis-
eases as an important transcription factor in CD4+CD25+ regulatory T
cells [1]. Recent studies proved that its expression was not restricted
to the lymphocyte lineage, but also in some non-lymphoid normal
and cancerous cells [2]. It has been known that FOXP3 functions as a
molecular scaffold recruiting other modiﬁers to the FOXP3-bound loci.
Some histone modiﬁcation enzymes, including TIP60, HDACs 7 and 9,
and EOS/CtBP1, have been found to be physically interacted with
FOXP3 to form a repressor complex [34,35]. Now FOXP3 has been dem-
onstrated to be an important tumor suppressor in breast cancers. Strong
Fig. 5. FOXP3 promoted Ezh2's degradation through K48-linkage ubiquitination. (A) Relative mRNA levels of miR-101 and Ezh2 in mouse lung ﬁbroblast cells at indicated passages
(n = 4) were measured by real-time quantitative PCR. (B) T47D/Ezh2/MigRI and T47D/Ezh2/FOXP3 cells (Supplementary material) were treated with cycloheximide (50 μg/ml)
for indicated time. The protein levels of myc-Ezh2 were analyzed by Western blot. (C) The effect of MG132 on the stability of Ezh2 in T47D/Ezh2/FOXP3 cells measured by Western
blot. (D) Ubiquitination of Ezh2 was analyzed by immunoprecipitation and Western blot in T47D/Ezh2/MigRI and T47D/Ezh2/FOXP3 cells. IP with anti-ubiquitin and IB with
anti-Myc antibodies demonstrated the promotion of FOXP3 on the polyubiquitination of Ezh2, and vice versa. * represents isotype IgG for immunoprecipitation. (E) Ubiquitination
of Ezh2 was analyzed in T47D/Ezh2/Ub/FOXP3 and T47D/Ezh2/Ub-K48R/FOXP3 cells (Supplementary material). IP with anti-Flag and IB with anti-Myc antibodies demonstrated the
impairment of ubiquitin K48R mutation on the formation of Ezh2 polyubiquitination, and vice versa. One representative experiment of three was shown for B, C, D and E. The blots
of heavy chain of antibodies indicated the equal amount of IP antibodies pulling down the targets (D and E).
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cancer-related genes, especially suppressor genes, including p21
[3,7,8]. But the mechanisms by which FOXP3 regulates suppressor
genes are not fully determined.
In this study, we observed that there was an inverse correlation in
various conditions between FOXP3 and histone methyltransferase
Ezh2. We demonstrated that FOXP3 could decrease Ezh2's promotion
of mammosphere formation, cell growth, directional migration, and
colony formation in T47D cells. FOXP3 could downregulate Ezh2,
which depended on not only the expression level, but also the nuclear
localization of FOXP3. miR-101 had been conﬁrmed to decrease Ezh2.
In this study we found that FOXP3 could upregulate miR-101. More
importantly, we demonstrated that FOXP3 promoted Ezh2 protein
degradation through K48-linkage ubiquitination by enhancing E3 li-
gase Praja1. Praja-1 has E2-dependent E3 ubiquitin–protein ligase ac-
tivity and belongs to a class of ubiquitin ligases that include a RING
ﬁnger motif [36]. Both Praja-1 (Xq13.1) and FOXP3 (Xp11.23) are lo-
cated on chromosome X. Whether the physically jacent locations
have any impacts on the enhanced transcription of Praja-1 by
FOXP3 need further investigation.
The cyclin-dependent kinase inhibitor (CDKI) p21 has been iden-
tiﬁed to be one of the main targets of FOXP3 in cancer cell lines
[8,36]. p21 pathway has been demonstrated as a barrier not only in
tumorigenicity, but also in induced pluripotent stem cell generation.
It was shown that forced expression of p21 markedly decreased plu-
ripotent stem cell generation and cancer stem cell-like gene expres-
sion [37,38]. Results from human breast cancer tissue microarray
revealed that FOXP3 and p21 expression showed a positive correla-
tion. FOXP3 directly occupied and activated the p21 promoter. This
occupation inhibited the binding of HDAC2 and HDAC4 to the site
and increased local histone H3 acetylation (Fig. 5s in the Supplemen-
tary material) [8]. Moreover, the suppression of cancer cell growth by
FOXP3 could be reversed by p21 shRNA, which strongly suggestedthat the activation of p21 contributes to FOXP3's tumor suppressor
function [8,35].
On the other hand, in contrast to other CDKI genes, p21 is rarely
mutated or deleted in tumors [39]. In addition, it was found that
p21 is rarely inactivated by its promoter methylation in lymphomas
and carcinomas, which suggested that chromatin/histone structure
changes were likely the alternative mechanisms in p21 inactivation
[40]. Ezh2 has been demonstrated to mediate tumor-suppressor si-
lencing in cancer potentially independent of promoter DNA methyla-
tion [41]. Sulforaphane, an active agent found in cruciferous
vegetables, caused a reduction in Ezh2 expression and increased
p21 expression in skin cancer cells [42]. p21 was demonstrated to
be upregulated after inhibition of Ezh2 in cervical cancer, melanoma
cells [13], and cell line used in the present study (Fig. 4s in the Sup-
plementary material). Recently, the interaction between Ezh2 and
p21 promoter was conﬁrmed by chromatin immunoprecipitation
assay in ovarian cancer cell lines [43]. Ezh2 depletion could remove
histone HDAC1 from the p21 transcriptional start site and down-
stream region, enhancing local histone 3 acetylation, leading to p21
activation (Fig. 5s in the Supplementary material) [13]. c-Myc, a neg-
ative target of FOXP3, is important in self-renewal of hematopoietic
stem cells [7,44]. It has also been demonstrated to be positively regu-
lated by Ezh2 in glioblastoma cancer stem cells [45] and T47D cells
used in this study (Fig. 4s in the Supplementary material). Whether
other targets of FOXP3, such as HER2/neu, SKP2 and SATB1, are regu-
lated by Ezh2 remains to be investigated.
Altogether, our study demonstrated the negative impacts of
FOXP3 on Ezh2 and identiﬁed FOXP3 as a negative regulator of
Ezh2 mainly on a post-translation level. These data suggested a fur-
ther role for FOXP3 in epigenetic regulation. The present study
bridged FOXP3 and Ezh2, especially in the chain of regulating p21
(Fig. 5s in the Supplementary material). We provided new mecha-
nisms for FOXP3 in chromatin remodeling as an Ezh2 suppressor
Fig. 6. FOXP3 bound andpromoted themRNA transcription of E3 ligase Praja1 directly.mRNA levels of Praja1weremeasured by real-time quantitative RT-PCR innon-tumorigenicMCF-10A
and tumorigenic T47D, MDA-MB-231 andMCF-7 cells (A, n = 3); starved MCF-10A cells (B, n = 3); doxycycline-responsive, FOXP3 conditionally-expressed T47D cells (C, n = 3); T47D
cells stably expressing FOXP3wild-type or K227Rmutant (D, n = 3); and T47D cells stably expressing FOXP3(E, n = 3) or with FOXP3 knockdown (F, n = 3). Cell line information can be
found in the Supplementary material. G. Schematic presentation shows three FOXP3 binding sites in the promoter region of Praja1 between−1030 and−618 bp upstream of translation
starting site. Dashed arrows indicate the location of the ChIP primers for “control” and “Praja1” (−1030/−618) respectively (upper part). ChIP analysis indicates that FOXP3 can interact
with the promoter region of Praja1 gene directly. DNA input: 1/20 DNA input; IP-FOXP3: immunoprecipitation by an antibody speciﬁc against FOXP3; and IgG: control IgG (lower part). H
and I. The effect on Ezh2's polyubiquitination by Praja1was analyzed by immunoprecipitation andWesternblot in T47D/Ezh2/Ub/pBabe (EV) andT47D/Ezh2/Ub/Praja1 (Praja1), andT47D/
Ezh2/Ub/Praja1/pLKO.1 (EV) and T47D/Ezh2/Ub/Praja1/shRNA-Praja1 (sh-RNA#2 , Fig. 2s in the Supplementarymaterial). The interaction between Ezh2 and Praja1was also conﬁrmed by
IP with anti-Myc (Ezh2) and IB with anti-HA (Praja1) (H). One representative experiment of three was shown.
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